Hodgkin Lymphoma
Hodgkin Lymphoma Untreated for Six Years Presenting with Tracheoesophageal Fistula
... Due to successful therapies, the natural history of untreated Hodgkin lymphoma is extremely di ffi cult to ascertain [3, 4]. Prior to establishing the potentially curative role of chemo- therapy, surgical ...
5
Treatment of Newly Diagnosed and Relapsed Hodgkin Lymphoma in Children
... German Hodgkin Lymphoma Study Group evaluated the safety and efficacy of rituximab in patients with relapsed lymphocyte-predominant Hodgkin lymphoma or other CD20 (+) subtypes of ...
7
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
... with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma ...Malignant Lymphoma in Lugano, Switzerland, in June 2011, that included leading hematologists, oncologists, radiation oncologists, ...
10
Genome-wide homozygosity signature and risk of Hodgkin lymphoma.
... Recent studies have reported that regions of homozygosity (ROH) in the genome are detectable in outbred populations and can be associated with an increased risk of malignancy. To examine whether homozygosity is ...
8
The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD
... We conducted a retrospective analysis of patients diagnosed with Hodgkin lymphoma at our institution from January, 2003 until July, 2015. The Mount Sinai Data Warehouse was used to collect all available ...
7
Expanded use of rituximab in the management of non-Hodgkin lymphoma
... CD20-positive lymphoma. In previously untreated non-Hodgkin lymphoma (NHL) conventional chemotherapy supplemented by rituximab (R-chemotherapy) was shown to be more effective than chemotherapy ...as ...
9
Hodgkin lymphoma
... Hodgkin lymphoma (HL) is one of the most frequent lymphomas in the Western world, with an annual incidence of about 3 cases per 100,000 ...as Hodgkin and Reed-Sternberg (HRS) cells, and in NLPHL they ...
10
Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review
... Abstract: Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) account for ~10% and 2%–3% of all cases of lymphoid neoplasms, respectively. Up to 30% of patients with HL are refractory or ...
8
The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma
... Abstract: There is no consensus on recommendations for the treatment of relapsed and refractory indolent non-Hodgkin lymphoma (NHL). Bendamustine hydrochloride (bendamustine) has recently been approved for ...
11
Aberrant expression of homeobox gene SIX1 in Hodgkin lymphoma
... In Hodgkin lymphoma (HL) we recently identified deregulated expression of homeobox genes MSX1 and OTX2 which are physiologically involved in development of the embryonal neural plate border ...
15
Prevalence of Hepatitis C virus Genotype 3a in patients with Hodgkin and Non-Hodgkin Lymphoma
... Patients. This retrospective study was carried out on 52 paraffin-embedded tissue blocks including 23/52 Hodgkin (44.23%) and 29/52 Non Hodgkin (55.77%) lymphomas. Tissue blocks were collected from archive ...
6
Gemcitabine-Based Treatment in Poor-Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma – a Multicenter Polish Experience
... Background. The treatment of patients with relapsed or refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) remains challenging. Gemcitabine is a cytidine analog with a wide ...
7
Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma
... (R/R) Hodgkin lymphoma (HL) or R/R systemic anaplastic large-cell lymphoma (sALCL) treated with brentuximab vedotin (BV) experienced high remission rates in two Phase II ...
8
Pediatric Non Hodgkin Lymphoma: A Retrospective 7 Year Experience in Children & Adolescents with Non Hodgkin Lymphoma Treated in King Fahad Medical City (KFMC)
... Non-Hodgkin’s lymphoma is an aggressive malignant disease in children and adoles- ...Non-Hodgkin lymphoma and its out- come in Saudi ...kin’s lymphoma treated at ...Non-Hodgkin’s ...
16
Non-Hodgkin Lymphoma Richard Orlowski, MD
... The American Cancer Society (ACS) estimates that 69,740 Americans will be diag- nosed with non-Hodgkin lymphoma (NHL) in 2013. Excluding non-melanoma skin cancers, it is the sixth most common cancer in this ...
7
Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances
... Classical Hodgkin lymphoma is considered a highly curable disease; however, 20% of patients cannot be cured with standard first-line chemotherapy and have a dismal ...fact, Hodgkin lymphoma ...
13
Health-related quality of life in Hodgkin lymphoma: a systematic review
... Vermaete et al. [47] conducted a longitudinal study to assess fatigue, physical activity and physical fitness in individuals with lymphoma before, during and after treatment. This study included 29 patients with ...
14
Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin
... for Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), novel therapeutic agents are needed for refrac- tory or relapsed ...
12
Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
... Hodgkin lymphoma is thought to arise from germinal center and post-germinal center B-cells, with tumors comprised of a minority of neoplastic (Reed-Sternberg) cells in an inflammatory background of a ...
7
Non-Hodgkin lymphoma and GIST: molecular pathways and clinical expressions
... cell lymphoma is a subtype of non-Hodgkin ...non-Hodgkin lymphoma and gastrointestinal stromal tumors, there is no common molecular pathway between these two ...
6